PL3938368T3 - Postacie związków chemicznych w zwiększonej biodostępności oraz ich preparaty - Google Patents

Postacie związków chemicznych w zwiększonej biodostępności oraz ich preparaty

Info

Publication number
PL3938368T3
PL3938368T3 PL20717027.5T PL20717027T PL3938368T3 PL 3938368 T3 PL3938368 T3 PL 3938368T3 PL 20717027 T PL20717027 T PL 20717027T PL 3938368 T3 PL3938368 T3 PL 3938368T3
Authority
PL
Poland
Prior art keywords
formulations
compound form
enhanced bioavailability
bioavailability
enhanced
Prior art date
Application number
PL20717027.5T
Other languages
English (en)
Inventor
Akm Nasir Uddin
Mandar Vasant DALI
Onkar Shripad VAZE
Original Assignee
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics, Inc. filed Critical Ptc Therapeutics, Inc.
Publication of PL3938368T3 publication Critical patent/PL3938368T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL20717027.5T 2019-03-11 2020-03-09 Postacie związków chemicznych w zwiększonej biodostępności oraz ich preparaty PL3938368T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962816402P 2019-03-11 2019-03-11
PCT/US2020/021648 WO2020185648A1 (en) 2019-03-11 2020-03-09 Compound form having enhanced bioavailability and formulations thereof

Publications (1)

Publication Number Publication Date
PL3938368T3 true PL3938368T3 (pl) 2023-12-27

Family

ID=70166162

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20717027.5T PL3938368T3 (pl) 2019-03-11 2020-03-09 Postacie związków chemicznych w zwiększonej biodostępności oraz ich preparaty

Country Status (20)

Country Link
US (1) US20220185795A1 (pl)
EP (1) EP3938368B1 (pl)
JP (1) JP2022524424A (pl)
KR (1) KR20210151061A (pl)
CN (1) CN113853374B (pl)
AU (1) AU2020235825A1 (pl)
BR (1) BR112021017353A2 (pl)
CA (1) CA3131801A1 (pl)
CL (1) CL2021002365A1 (pl)
CO (1) CO2021011836A2 (pl)
EA (1) EA202192167A1 (pl)
EC (1) ECSP21067104A (pl)
HU (1) HUE062796T2 (pl)
IL (1) IL286163A (pl)
MX (1) MX2021010906A (pl)
PE (1) PE20212270A1 (pl)
PL (1) PL3938368T3 (pl)
SG (1) SG11202109503TA (pl)
WO (1) WO2020185648A1 (pl)
ZA (1) ZA202106437B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12015501130B1 (en) * 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス, インコーポレイテッド 膵臓癌を治療する方法
AU2020227748A1 (en) * 2019-02-28 2021-09-16 Ptc Therapeutics, Inc. Method for treating a multiple myeloma
CA3134648A1 (en) * 2019-03-27 2020-10-01 Ptc Therapeutics, Inc. Combinations useful in a method for treating sarcoma
EP4065090A1 (en) * 2019-11-26 2022-10-05 Ikena Oncology, Inc. Ahr inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12015501130B1 (en) * 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
NZ708272A (en) * 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
WO2016155655A1 (zh) * 2015-04-03 2016-10-06 上海瑛派药业有限公司 Parp抑制剂固体药物剂型及其应用
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide

Also Published As

Publication number Publication date
ZA202106437B (en) 2025-01-29
HUE062796T2 (hu) 2023-12-28
PE20212270A1 (es) 2021-11-30
MX2021010906A (es) 2021-10-01
SG11202109503TA (en) 2021-09-29
EA202192167A1 (ru) 2022-01-12
CN113853374B (zh) 2025-02-28
CA3131801A1 (en) 2020-09-17
CN113853374A (zh) 2021-12-28
EP3938368B1 (en) 2023-06-07
IL286163A (en) 2021-10-31
US20220185795A1 (en) 2022-06-16
BR112021017353A2 (pt) 2021-11-16
WO2020185648A1 (en) 2020-09-17
ECSP21067104A (es) 2021-11-18
CO2021011836A2 (es) 2021-12-10
EP3938368A1 (en) 2022-01-19
KR20210151061A (ko) 2021-12-13
AU2020235825A1 (en) 2021-09-30
JP2022524424A (ja) 2022-05-02
CL2021002365A1 (es) 2022-04-22

Similar Documents

Publication Publication Date Title
ZA202106612B (en) Compounds and conjugates thereof
IL286163A (en) Compound form with enhanced bioavailability and formulations thereof
IL285078A (en) Delicious formulations
IL287224A (en) New formulations containing melphalan
LT4233850T (lt) Kapsulių preparatai
GB201915094D0 (en) New formulations
IL290356A (en) Formulations for Resotide
ZA202006570B (en) Pharmaceutical formulations
GB201904338D0 (en) Fluorouracil-containing formulations
GB202117828D0 (en) New formulations
IL284691A (en) formulations
EP3716766A4 (en) BENZOXABOROLE COMPOUNDS AND THEIR FORMULATIONS
SG11202010792TA (en) Improved pharmaceutical formulations
IL287316A (en) compounds and preparations
GB202009685D0 (en) Formulations
GB202103785D0 (en) Formulations
GB202018889D0 (en) Formulations
GB202009684D0 (en) Formulations
HK40065292A (en) Compound form having enhanced bioavailability and formulations thereof
GB201910092D0 (en) New formulations
GB202115127D0 (en) Formulations
GB202115121D0 (en) Formulations
GB202103762D0 (en) Formulations
GB202103780D0 (en) Formulations
GB202018250D0 (en) Formulations